Date | Price Target | Rating | Analyst |
---|---|---|---|
7/15/2024 | $39.00 → $30.00 | Equal-Weight → Underweight | Morgan Stanley |
5/30/2024 | $36.00 | Neutral | Goldman |
5/10/2024 | $40.00 | Buy → Hold | TD Cowen |
5/30/2023 | $45.00 | Equal-Weight | Morgan Stanley |
3/29/2023 | $43.00 | Neutral | UBS |
1/6/2023 | $55.00 | Overweight → Equal-Weight | Morgan Stanley |
1/5/2023 | Outperform → Mkt Perform | Raymond James | |
1/3/2023 | $66.00 → $55.00 | Buy → Neutral | BofA Securities |
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
Morgan Stanley downgraded Baxter from Equal-Weight to Underweight and set a new price target of $30.00 from $39.00 previously
Goldman initiated coverage of Baxter with a rating of Neutral and set a new price target of $36.00
TD Cowen downgraded Baxter from Buy to Hold and set a new price target of $40.00
8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
Second-quarter sales from continuing operations of $3.81 billion increased 3% on a reported basis and 4% on a constant currency basis, exceeding the company's previously issued guidance and delivering constant currency growth across all segments1 Second-quarter U.S. GAAP2 diluted earnings per share (EPS) from continuing operations were ($0.62) and adjusted diluted EPS from continuing operations were $0.68, exceeding the company's previously issued guidance Baxter increases its full-year sales guidance and now expects sales growth of approximately 3% on both a reported and constant currency basis Baxter increases its full-year adjusted diluted EPS guidance and now expects adjusted
Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2024 financial results on Tuesday, August 6, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I898552708 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's leadi
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on Oct. 1, 2024, to stockholders of record as of Aug. 30, 2024. The indicated annual dividend rate is $1.16 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersecti
Addition of Mr. Craig complements current board expertise with deep financial, broad operational and public company board experience Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Jeffrey (Jay) A. Craig, former executive chair and chief executive officer (CEO) of Meritor Corporation, to its board of directors. Mr. Craig will serve on Baxter's Audit Committee. His appointment is effective today and brings the total number of directors serving the company to 12. "We are excited to welcome Jay to Baxter's board," said José (Joe) E. Almeida, chair, president and CEO. "As a former CEO, CFO, COO and public company auditor, Jay's broad-based busin
Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Joel Grade as executive vice president and chief financial officer (CFO), reporting to Baxter chairman, president and CEO, José (Joe) E. Almeida, effective Oct. 18, 2023. At that time, Brian Stevens, who has served as the company's interim CFO since May 31, 2023, will transition to his prior role as senior vice president, chief accounting officer and controller. "Joel is a seasoned global financial executive with decades of deep operational and broad business experience as well as a proven record of results-driven impact," said Mr. Almeida. "I am confident we will benefit from Joel's leadership
Addition of Mr. Craig complements current board expertise with deep financial, broad operational and public company board experience Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Jeffrey (Jay) A. Craig, former executive chair and chief executive officer (CEO) of Meritor Corporation, to its board of directors. Mr. Craig will serve on Baxter's Audit Committee. His appointment is effective today and brings the total number of directors serving the company to 12. "We are excited to welcome Jay to Baxter's board," said José (Joe) E. Almeida, chair, president and CEO. "As a former CEO, CFO, COO and public company auditor, Jay's broad-based busin
TORONTO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion ("PMX") in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: Robust enrollment into the second half of 2024, which continues the pace experienced since January 2024: 129 patients enrolled at end of August 2024 Four patients enrolled in August, which is a typically slow period for clinical trial activity
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 1:30 p.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Tuesday, March 4, 2025. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been opera
Ares Management Corp. (NYSE:ARES) and HPS Investment Partners are spearheading a $3 billion credit facility to finance Carlyle Group Inc.’s (NASDAQ:CG) potential acquisition of Baxter International Inc.’s (NYSE:BAX) kidney-care division. This debt package includes a $2.5 billion unitranche loan and a $450 million revolver. Oaktree Capital Management is also involved in the financing, and smaller lenders may participate after signing. Also Read: Medical Devices Giant Baxter Secures FDA Approval For New Infusion Pump System. The financing terms suggest an interest rate five percentage points above the Secured Overnight Financing Rate, placing the division Vantive’s leverage at 4.2
https://www.bloomberg.com/news/articles/2024-07-23/ares-hps-line-up-3-billion-debt-for-carlyle-s-baxter-unit-bid?sref=y3YMCJ4e
- Reuters
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
3 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)